Last reviewed · How we verify

Quadrivalent VLP Vaccine

Medicago · Phase 3 active Biologic

This quadrivalent VLP vaccine induces an immune response against four different strains of the influenza virus.

This quadrivalent VLP vaccine induces an immune response against four different strains of the influenza virus. Used for Influenza prevention.

At a glance

Generic nameQuadrivalent VLP Vaccine
SponsorMedicago
ModalityBiologic
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

The vaccine uses virus-like particles (VLPs) to stimulate the body's immune system, producing antibodies that can recognize and neutralize the influenza virus. This provides protection against infection and reduces the severity of symptoms if the virus is contracted.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: